Profile
| Metric | Value |
|---|---|
| Full Name | Arcus Biosciences, Inc. |
| Ticker | NYSE: RCUS |
| Exchange | NYSE |
| Sector | Healthcare |
| Industry | Biotechnology |
| Country | United States |
| IPO | |
| Indexes | Not included |
| Website | arcusbio.com |
| Employees | 627 |
Key Metrics
| Metric | Date | Value |
|---|---|---|
| Price | $23.20 | |
| Price, 1D Change | +6.96% | |
| Market Cap | $3B | |
| - | ||
| PE Ratio | - | |
| Beta | 1.35 | |
| Revenue | $258M | |
| Revenue, 1Y Change | +120.51% | |
| EPS | -$3.14 | |
| EPS, 1Y Change | +24.29% |
Chart
Add series to chart(max: 6)
Series
SUGGESTED SERIES
Events
| Metric | Date | Value |
|---|---|---|
| Next Earnings | ||
| Last Qtr. Earnings | ||
| Last Ann. Earnings | ||
| Last Ex-Dividend | N/A | N/A |
| Next Ex-Dividend | N/A | N/A |
| Last Split | N/A | N/A |
| Next Split | N/A | N/A |
| Last Ticker Change | N/A | N/A |
| Next Ticker Change | N/A | N/A |
🔒 Log In To Unlock Full Data
Estimates
| Metric | Date | Value |
|---|---|---|
| EPS | -$3.14 | |
| EPS Estimate | -$3.50 | |
| EPS Est. Change | -11.43% | |
| Revenue | $258.00M | |
| Revenue Estimate | $237.50M | |
| Revenue Est. Change | -7.95% | |
| Current Price | $23.20 | |
| Price Target | - | $31.00 |
| Price Tgt. Change | - | +33.62% |
🔒 Log In To Unlock Full Data
EPS
| Year | Estimate | Reported | Surprise / Exp. |
|---|---|---|---|
| -$4.00 | -$4.15 | -3.72% | |
| -$3.24 | -$3.14 | +3.07% | |
| -$3.50 | N/A | -11.43% | |
| -$3.87 | N/A | -23.13% |
Revenue
| Year | Estimate | Reported | Surprise / Exp. |
|---|---|---|---|
| $113.88M | $117.00M | +2.74% | |
| $261.59M | $258.00M | -1.37% | |
| $237.50M | N/A | -7.95% | |
| $118.80M | N/A | -53.95% |
🔒 Log In To Unlock Full Data
Performance
| Metric | Date | Value |
|---|---|---|
| Price, 1Y | +52.23% | |
| Price, 3Y | +25.54% | |
| Market Cap, 1Y | +104.29% | |
| Market Cap, 3Y | +113.07% | |
| Revenue, 1Y | +120.51% | |
| Revenue, 3Y | -32.62% | |
| EPS, 1Y | +24.29% | |
| EPS, 3Y | -539.79% |
🔒 Log In To Unlock Full Data
Technical Indicators
| Metric | Date | Value |
|---|---|---|
| Current Price | $23.20 | |
| SMA 200 | $13.21 | |
| SMA 200 vs Price | -43.08% | |
| SMA 50 | $22.27 | |
| SMA 50 vs Price | -4.00% | |
| Beta | 1.35 | |
| ATR | $1.26 | |
| 14-Day RSI | 52.85 | |
| 10-Day Volatility | 56.34% | |
| 1-Year Volatility | 63.57% |
Dividends
| Metric | Date | Value |
|---|---|---|
| N/A | - | |
| Upcoming | N/A | N/A |
| - | ||
| - | ||
| Dividends Paid | $0.00 | |
| Payout Ratio | 0.00% |
🔒 Log In To Unlock Full Data
Income & Profitability
| Metric | Date | Value |
|---|---|---|
| Revenue | $258.00M | |
| EPS | -$3.14 | |
| Gross Profit | $248.00M | |
| Gross Margin | 96.12% | |
| Operating Profit | -$310.00M | |
| Operating Margin | -120.16% | |
| Net Income | -$283.00M | |
| Net Margin | -109.69% | |
| EBITDA | -$269.00M |
🔒 Log In To Unlock Full Data
Financial Health
| Metric | Date | Value |
|---|---|---|
| Debt To Equity | 0.33 | |
| Current Ratio | 4.50 | |
| Quick Ratio | 4.50 | |
| - | ||
| F-Score | 0 | |
| Altman Z-Score | 1.46 |
Valuations
| Metric | Date | Value |
|---|---|---|
| PE Ratio | - | |
| PS Ratio | 11.96 | |
| PB Ratio | 6.58 | |
| EV/EBITDA | -5.89 | |
| Enterprise Value | N/A | - |
Balance Sheet
| Metric | Date | Value |
|---|---|---|
| Book Value | $485.00M | |
| Cash & Equivalents | $150.00M | |
| Total Assets | $1.15B | |
| Current Assets | $1.02B | |
| Total Liabilities | $665.00M | |
| Current Liabilities | $226.00M | |
| Total Debt | $159.00M | |
| Short Term Debt | $12.00M | |
| Accounts Payable | $18.00M |
Expenses
| Metric | Date | Value |
|---|---|---|
| Total Expenses | $568.00M | |
| Operating Expenses | $568.00M | |
| Cost Of Goods Sold | $10.00M | |
| SG&A | $120.00M | |
| D&A | $10.00M | |
| Interest Expense | $0.00 | |
| Income Tax | $1.00M |
Cash Flow
| Metric | Date | Value |
|---|---|---|
| CFO | -$170.00M | |
| CFI | -$84.00M | |
| CFF | $277.00M | |
| Capex | $6.00M | |
| Free Cash Flow | -$176.00M |
Recent analyst updates
| Metric | Date | Value |
|---|---|---|
| HC Wainwright & Co. | → | |
| B of A Securities | → | |
| Goldman Sachs | → | |
| HC Wainwright & Co. | → | |
| Citigroup | → | |
| Wells Fargo | → | |
| Citigroup | → | |
| Truist Securities | → | |
| Wells Fargo | → | |
| Morgan Stanley | → |
Analyst sentiment
Institutional ownership
Screeners with RCUS
Data Sources & References
- RCUS Official Website www.arcusbio.com
- Most Recent Quarterly Report (10-Q) www.sec.gov/Archives/edgar/data/1724521/000172452125000116/0001724521-25-000116-index.htm
- Most Recent Annual Report (10-K) www.sec.gov/Archives/edgar/data/1724521/000172452125000040/0001724521-25-000040-index.htm
- RCUS Profile on Yahoo Finance finance.yahoo.com/quote/RCUS
- RCUS Profile on NASDAQ.com www.nasdaq.com/market-activity/stocks/rcus
FAQ
What is the ticker symbol for Arcus Biosciences, Inc.?
The ticker symbol for Arcus Biosciences, Inc. is NYSE:RCUS
Does Arcus Biosciences, Inc. pay dividends?
No, Arcus Biosciences, Inc. does not pay dividends
What sector is Arcus Biosciences, Inc. in?
Arcus Biosciences, Inc. is in the Healthcare sector
What industry is Arcus Biosciences, Inc. in?
Arcus Biosciences, Inc. is in the Biotechnology industry
What country is Arcus Biosciences, Inc. based in?
Arcus Biosciences, Inc. is headquartered in United States
When did Arcus Biosciences, Inc. go public?
Arcus Biosciences, Inc. initial public offering (IPO) was on March 15, 2018
Is Arcus Biosciences, Inc. in the S&P 500?
No, Arcus Biosciences, Inc. is not included in the S&P 500 index
Is Arcus Biosciences, Inc. in the NASDAQ 100?
No, Arcus Biosciences, Inc. is not included in the NASDAQ 100 index
Is Arcus Biosciences, Inc. in the Dow Jones?
No, Arcus Biosciences, Inc. is not included in the Dow Jones index
When was Arcus Biosciences, Inc. last earnings report?
Arcus Biosciences, Inc.'s most recent earnings report was on October 28, 2025
When does Arcus Biosciences, Inc. report earnings?
The next expected earnings date for Arcus Biosciences, Inc. is February 24, 2026